<?xml version="1.0" encoding="utf-8"?>
<items><story><date>09:46 03 January 2007 (UTC)</date><text>Jan 3 Mylan Laboratories Inc. MYL.N, a maker
of generic drugs, said it received U.S. Food and Drug
Administration approval to market Levothyroxine sodium tablets
as a bioequivalent to Levothroid tablets, which treats
deficiency of thyroid activity. Mylan said in a statement that Levothyroxine sodium tablets
are approved to treat hypothyroidism and pituitary TSH
suppression.
 (Reporting by Dilipp S. Nag in Bangalore)


</text><link>http://www.reuters.com/article/2007/01/03/mylan-fda-idUSWNAS661020070103</link><sectors><value><value>Regulatory News</value></value></sectors><title>mylan gets fda ok to market levothyroxine sodium tablets</title></story></items>